OstiFen (Carprofen) Injection for Dogs

OstiFen Injection (carprofen) is used for pain and inflammation of osteoarthritis and postoperative pain after soft tissue and orthopedic surgeries in dogs.

OstiFen Carprofen Injection is a clean solution that contains carprofen, which is a non-steroidal anti-inflammatory drug (NSAID) from the propionic acid class, similar to ibuprofen, naproxen, and ketoprofen.

• To alleviate pain and reduce inflammation linked to osteoarthritis (OA)
• To manage postoperative pain from soft tissue and orthopedic surgeries in dogs.
• There is 50 mg of carprofen in every milliliter of injectable solution provided.
• Offered in 20 mL and unique 50 mL containers.
• Substantial reduction in costs for each procedure

Indication:

OstiFen Injection is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.

Prescription items are NON-RETURNABLE and NON-REFUNDABLE.

Please note product may arrive in a Hardy Paw Pharmacy vial, manufacturer packaging is shown for reference.

Dosage and Administration

Carefully consider the potential benefits and risks of carprofen and other treatment options before deciding to use OstiFen Injection. Use the lowest effective dose for the shortest duration consistent with individual response. The recommended dosage for subcutaneous administration to dogs is 2 mg/lb (4.4 mg/kg) of body weight daily. The total daily dose may be administered as either 2 mg/lb of body weight once daily or divided and administered as 1 mg/lb (2.2 mg/kg) twice daily. For control of postoperative pain, administer approximately 2 hours before the procedure.

Contraindications:

Carprofen should not be used in dogs exhibiting previous hypersensitivity to carprofen.

Warnings:

Keep out of reach of children. Not for human use. Consult a physician in cases of accidental human exposure. For use in dogs only. Do not use it in cats.

All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data before, and periodically during, administration of any NSAID should be considered. Owners should be advised to observe for signs of potential drug toxicity.

Precautions:

As a class, cyclooxygenase-inhibitory NSAIDs may be associated with gastrointestinal, renal, and hepatic toxicity. Effects may result from decreased prostaglandin production and inhibition of the enzyme cyclooxygenase which is responsible for the formation of prostaglandins from arachidonic acid.11-14 When NSAIDs inhibit prostaglandins that cause inflammation they may also inhibit those prostaglandins which maintain normal homeostatic function. These anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease more often than in healthy patients.12,14 NSAID therapy could unmask occult disease which has previously been undiagnosed due to the absence of apparent clinical signs. Patients with underlying renal disease, for example, may experience exacerbation or decompensation of their renal disease while on NSAID therapy.11-14 The use of parenteral fluids during surgery should be considered to reduce the potential risk of renal complications when using NSAIDs perioperatively.

Carprofen is an NSAID, and as with others in that class, adverse reactions may occur with its use. The most frequently reported effects have been gastrointestinal signs. Events involving suspected renal, hematologic, neurologic, dermatologic, and hepatic effects have also been reported. Patients at greatest risk for renal toxicity are those who are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be approached cautiously, with appropriate monitoring. Concomitant use of carprofen with other anti-inflammatory drugs, such as other NSAIDs or corticosteroids, should be avoided because of the potential increase of adverse reactions, including gastrointestinal ulcerations and/or perforations. Sensitivity to drug-associated adverse reactions varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Carprofen treatment was not associated with renal toxicity or gastrointestinal ulceration in well-controlled safety studies of up to ten times the dose in healthy dogs. As with any parenterally injected product, good hygienic procedures should be used when administering OstiFen Injection. It is suggested to use different sites for additional injections.

OstiFen Injection is not recommended for use in dogs with bleeding disorders (e.g., Von Willebrand's disease), as safety has not been established in dogs with these disorders. The safe use of OstiFen Injection in animals less than 6 weeks of age, pregnant dogs, dogs used for breeding purposes, or in lactating bitches has not been established. Safety has not been established for IV or IM administration. Studies to determine the activity of carprofen when administered concomitantly with other protein-bound or similarly metabolized drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring additional therapy. Such drugs commonly used include cardiac, anticonvulsant, and behavioral medications. It has been suggested that carprofen treatment may reduce the inhalant anesthetics needed.15 If additional pain medication is warranted after administration of the total daily dose of carprofen, alternative analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.

Information for Dog Owners

OstiFen Injection, like other drugs of its class, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include decreased appetite, vomiting, diarrhea, dark or tarry stools, increased water consumption, increased urination, pale gums due to anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes. Serious adverse reactions associated with this drug class can occur without warning and in rare situations result in death. Owners should be advised to discontinue OstiFen Injection therapy and contact their veterinarian immediately if signs of intolerance are observed. The vast majority of patients with drug-related adverse reactions have recovered when the signs are recognized, the drug is withdrawn and veterinary care, if appropriate, is initiated. Owners should be advised of the importance of periodic follow-up for all dogs during the administration of any NSAID.

Storage

Store under refrigeration at 36° to 46°F (2° to 8°C). Once broached, the product may be stored at temperatures up to 77°F (25°C). Use within 56 days of first puncture.